Details for New Drug Application (NDA): 212071
✉ Email this page to a colleague
NDA 212071 describes CUPRIC CHLORIDE, which is a drug marketed by Exela Pharma, Rk Pharma, Somerset, and Hospira, and is included in four NDAs. It is available from four suppliers. Additional details are available on the CUPRIC CHLORIDE profile page.
The generic ingredient in CUPRIC CHLORIDE is cupric chloride. Five suppliers are listed for this compound. Additional details are available on the cupric chloride profile page.
The generic ingredient in CUPRIC CHLORIDE is cupric chloride. Five suppliers are listed for this compound. Additional details are available on the cupric chloride profile page.
Summary for 212071
| Tradename: | CUPRIC CHLORIDE |
| Applicant: | Exela Pharma |
| Ingredient: | cupric chloride |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212071
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CUPRIC CHLORIDE | cupric chloride | INJECTABLE;INJECTION | 212071 | ANDA | Exela Pharma Sciences, LLC | 51754-0103 | 51754-0103-3 | 10 VIAL, SINGLE-DOSE in 1 CARTON (51754-0103-3) / 10 mL in 1 VIAL, SINGLE-DOSE |
| CUPRIC CHLORIDE | cupric chloride | INJECTABLE;INJECTION | 212071 | ANDA | Exela Pharma Sciences, LLC | 51754-0103 | 51754-0103-4 | 25 VIAL, SINGLE-DOSE in 1 CARTON (51754-0103-4) / 10 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 0.4MG COPPER/ML | ||||
| Approval Date: | Oct 31, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
